Literature DB >> 22246869

Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.

Linda Pax Lowes1, Lindsay Alfano, Laurence Viollet, Xiomara Quintero Rosales, Zarife Sahenk, Brian K Kaspar, K Reed Clark, Kevin M Flanigan, Jerry R Mendell, Michael P McDermott.   

Abstract

INTRODUCTION: In this study we address the challenging issue of potential use of muscle strength to predict function in clinical trials. This has immediate relevance to translational studies that attempt to improve quadriceps strength in sporadic inclusion-body myositis (sIBM).
METHODS: Maximum voluntary isometric contraction testing as a measure of muscle strength and a battery of functional outcomes were tested in 85 ambulatory subjects with sIBM.
RESULTS: Marked quadriceps weakness was noted in all patients. Strength was correlated with distance walked at 2 and 6 minutes. Additional correlations were found with time to get up from a chair, climb stairs, and step up on curbs.
CONCLUSIONS: Quadriceps (knee extensor) strength correlated with performance in this large cohort of sIBM subjects, which demonstrated its potential to predict function in this disease. These data provide initial support for use of muscle strength as a surrogate for function, although validation in a clinical trial is required.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22246869      PMCID: PMC3874796          DOI: 10.1002/mus.22321

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  33 in total

1.  Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.

Authors: 
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

2.  Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Michel D Ferrari; Aeilko H Zwinderman; Judith A M Wessels; Ferdinand C Breedveld; Pieter A van Doorn; Baziel G M van Engelen; Jessica E Hoogendijk; Chris J Höweler; Aeiko E de Jager; Frans G I Jennekens; Peter J Koehler; Marianne de Visser; Alain Viddeleer; Jan J Verschuuren; Axel R Wintzen
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

3.  Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.

Authors:  C Lindberg; E Trysberg; A Tarkowski; A Oldfors
Journal:  Neurology       Date:  2003-07-22       Impact factor: 9.910

4.  Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis.

Authors: 
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

5.  A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group.

Authors: 
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

Review 6.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

7.  Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.

Authors:  M C Dalakas; B Sonies; J Dambrosia; E Sekul; E Cupler; K Sivakumar
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

8.  A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group.

Authors:  R Tawil; M P McDermott; S Pandya; W King; J Kissel; J R Mendell; R C Griggs
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

9.  Inclusion body myositis: treatment with intravenous immunoglobulin.

Authors:  A A Amato; R J Barohn; C E Jackson; E J Pappert; Z Sahenk; J T Kissel
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

10.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.

Authors:  J R Mendell; R T Moxley; R C Griggs; M H Brooke; G M Fenichel; J P Miller; W King; L Signore; S Pandya; J Florence
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

View more
  7 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion.

Authors:  Jerry R Mendell; Louis G Chicoine; Samiah A Al-Zaidy; Zarife Sahenk; Kelly Lehman; Linda Lowes; Natalie Miller; Lindsay Alfano; Beverly Galliers; Sarah Lewis; Darren Murrey; Ellyn Peterson; Danielle A Griffin; Kathleen Church; Sharon Cheatham; John Cheatham; Mark J Hogan; Louise R Rodino-Klapac
Journal:  Hum Gene Ther       Date:  2019-04-19       Impact factor: 5.695

3.  Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.

Authors:  Katy Eichinger; Chad Heatwole; Susanne Heininger; Nikia Stinson; Carly Matichak Stock; Carla Grosmann; Kathryn R Wagner; Rabi Tawil; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2016-12-05       Impact factor: 3.217

Review 4.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423

5.  Assessing function and endurance in adults with spinal and bulbar muscular atrophy: validity of the adult myopathy assessment tool.

Authors:  Michael O Harris-Love; Lindsay Fernandez-Rhodes; Galen Joe; Joseph A Shrader; Angela Kokkinis; Alison La Pean Kirschner; Sungyoung Auh; Cheunju Chen; Li Li; Ellen Levy; Todd E Davenport; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Rehabil Res Pract       Date:  2014-05-05

Review 6.  Update in inclusion body myositis.

Authors:  Pedro Machado; Stefen Brady; Michael G Hanna
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

Review 7.  Ongoing developments in sporadic inclusion body myositis.

Authors:  Pedro M Machado; Mhoriam Ahmed; Stefen Brady; Qiang Gang; Estelle Healy; Jasper M Morrow; Amanda C Wallace; Liz Dewar; Gita Ramdharry; Matthew Parton; Janice L Holton; Henry Houlden; Linda Greensmith; Michael G Hanna
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.